65岁西班牙人成为赛诺菲史上首位女CEO，消息公布后股价下跌

Group 1 - Sanofi announced the appointment of Belén Garijo as its new CEO, making her the first female CEO in the company's history, effective after the annual shareholders' meeting on April 29, 2026 [2] - Following the announcement, Sanofi's stock price fell by 4.5%, indicating market skepticism regarding the new appointment [2] - Garijo has a background as the CEO of Merck and has previously worked at Sanofi for 15 years, but her tenure at Merck was marked by limited success in new drug development, with only three new drugs launched [2][3] Group 2 - Sanofi faces significant pressure to improve its drug development pipeline, which has stagnated in recent years, contributing to a stock price decline of over 25% in the past year [3] - The company's key revenue-generating drug, Dupixent, will face patent expiration in about five years, and Sanofi has not identified a suitable replacement, adding to its challenges [4] - Vaccines, another core business for Sanofi, account for nearly one-fifth of its revenue but are also under pressure due to a hostile attitude from U.S. health authorities [4]